Want to *see* how a tumour has evolved and grown? And also how different clones acquired characteristic transcriptional and histopathological features?
Jessica Svedlund developed a base-specific extension of the in situ sequencing protocol (BaSISS) to detect somatic mutations on a microscopy slide with fluorescently tagged padlock probes. 2/9
These signals are denoised and assembled into microscopic maps of subclonal growth using @LomakinAI's rigorous machine learning model. 3/9
The results are eye watering (for me at least) and show the record of a raging competition of breast cancer clones. The observed clonal growth tightly followed physiological tissue structures. 4/9
What’s more, layering in ISS probes targeting gene transcripts reveals each clone’s gene expression program and what type of micro environment it surrounds itself with. 5/9
Clones can also have distinct histopathological appearance, further corroborating their phenotypic divergence. 6/9
Mapping these phenotypic patterns onto the underlying phylogeny brings an order into the observed heterogeneity and reveals directional changes as a tumour progresses. 7/9
These snippets highlight the huge potential of spatial genomics and transcriptomics with BaSISS to study cancer evolution. This will enable us to measure, understand - and hopefully one day prevent - the key steps of malignant progression. 8/9
There are some signs now that XBB.1.5 is loosing steam as it spreads through the wider population.
The share of cases has increased more slowly in the US and UK, recently.
A speculative thread why this might be.
In slowing down XBB.1.5 follows a pattern that has been noted also for BQ.1.1 or XBB.1.1.
Their initial fitness (daily increase of variant share) was higher than their long term advantage in a multi-lineage model with constant differences between variants (coloured lines).
In fact this slowing was observed for almost every Omicron lineage.
There is large variation between countries though, in part because of the low numbers at low incidence.
But the trends are clear that the initial growth rates dropped down on average between 0.02 to 0.04.
* BQ.1.1 spreads, albeit at the low end of expectations
* XBB* and BQ* lineages are the most widespread
* Further new variants have been defined, including CK.2.1.1 leading to complex patterns
While the initial estimates of BQ.1.1's growth advantage to BA.5 were between 10-15%, the estimate has come down to ~10% more recently.
As other more transmissible variants such as BF.7 have also spread the current fitness is lower, around 6-7%.
CK.2.1.1 came a bit out of the blue but is also contributing a measurable share of cases in countries such as Spain (~9%) and Germany (~3%).
It spreads at a similar rate as BQ.1, which it also matches in terms of key RBD mutations as shown below